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A phase I/IIA clinical trial with the chimeric mouse-human monoclonal antibody CGP 47 439
to the principal neutralization determinant in the V3 region of human immunodeficiency virus
type 1 (HIV-1) strain IIIB envelope protein gp 120 is reported. The trial was an uncontrolled
single-center, open-label, multidose tolerability, immunogenicity, and pharmacokinetic study in
homosexual men with advanced HIV disease. Patient groups were formed on the basis of the
reactivity of the antibody with the gp 120 of their HIV-1 isolates. Intravenous infusions of 1, 10,
and 25 mg of antibody were followed by seven escalated doses of 50, 100, and 200 mg, every 3
weeks. The antibody was well tolerated; no toxicity was observed. Some patients showed a tran-
sient but insignificant antibody response to the antibody with no apparent adverse reactions or
accelerated elimination of it. Substantial serum levels of the antibody were maintained with a
mean (1/2(3 of 8-16 days. A virus burden reduction was observed in some patients.
There is evidence that neutralizing antibodies playa role
in prevention of human immunodeficiency virus type I
(HIV-l) infection and in delaying disease progression. In
symptomatic primary infection, plasma and cellular viremia
decrease while the levels of HI V-I antibodies rise [1,2]. Pas-
sive immunization is known to be effective for certain viral
diseases [3-6]. In patients with AIDS or AIDS-related com-
plex, the administration of plasma containing hyperimmune
immunoglobulins can reduce viremia and delay disease pro-
gression [7-10]. Furthermore, studies with animal models
support evidence that antibodies may prevent HIV-l infec-
tion and related immunodeficiency viruses. Chimpanzees
were protected from challenge with HIV-I by a mouse-hu-
man chimeric antibody elicited against the principal neutral-
izing determinant (PND) in the V3 region of the homologous
strain [II]. In cynomolgus monkeys challenged with simian
immunodeficiency virus and HIV-2, infection was prevented
by administration of the respective antisera [12]. In humans,
the use of hyperimmune globulin from asymptomatic in-
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fected persons is beset with potential problems relating to
production, availability, safety. and quality control. There-
fore, monoclonal HIV-l neutralizing antibodies are being
considered as a possible alternative for passive immuniza-
tion.
We conducted a phase IIIIA trial ofa chimeric mouse-hu-
man monoclonal antibody (MAb; CGP 47 439) directed to
the V3 loop of HIV-l gp120. The antibody was intrave-
nously infused into 12 homosexual men with advanced HIV
disease. The variable regions of this chimeric antibody are
derived from BAT 123, a mouse MAb specific for the PND of
HIV-I IlIB and HIV-I MN [13, 14]. Preclinical data showed that
the mouse and chimeric antibodies had almost identical spec-
ificity and reactivity in antigen binding. in vitro neutraliza-
tion of HIV-I infectivity, and inhibition of the fusion be-
tween uninfected CD4+ cells and HIV-l-infected cells to
form syncytia [13, IS]. However. unlike BAT 123. the anti-
body also mediated antibody-dependent cellular cytotoxicity
in vitro.
Both the chimeric antibody and BAT 123 protected mice
with severe combined immunodeficiency transplanted with
normal human peripheral blood leukocytes (hu-PBL-SCID
mice [16, 17]) from infection with HIV-I [18]. Preclinical
toxicity testing of the antibody in rats and cynomolgus mon-
keys revealed no pyrogenicity, excellent tolerability, and ab-
sence of immunogenicity [19]. Studies of this chimeric anti-
body in cynomolgus monkeys also demonstrated favorable
pharmacokinetic properties [20].
These encouraging preclinical data warranted a clinical
trial to test the tolerability, immunogenicity. and pharmaco-
kinetic properties ofthe chimeric antibody in humans. Surro-
gate markers (e.g., virus load. CD4+ cell numbers. neopterin,
and /32-microglobulin) were also monitored. Participants
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Figure 1. Study design. Column I: patient treatment groups and pretrial stage (St) of opportunistic infections (lV-C 1, IV-C2. or IV-0)
according to Centers for Disease Control and Prevention (CDC) classification system; boxes with CL C2. or D indicate changes in level of
opportunistic infections during and after trial. Column 2: zidovudine (ZDV) withdrawal before trial. Columns 3 and 4: dosing (vertical bars)
was done sequentially with I week between groups, fully escalated within 6 weeks. Patients then received 6 more infusions of their high
dose. Column 5: ZDV boxes indicate approximate time (93 weeks after trial) zidovudine treatment resumed by patients. G and M never
resumed zidovudine. Patients C-E died.
could not receive antiretroviral therapy for at least 4 weeks
before. during. and 3 weeks after the trial.
Materials and Methods
Patient Enrollment and Study Design
Participants (men ~ 18 years old) were selected from the Zur-
ich AIDS patient cohort study [21]. They had stage IV (ad-
vanced) HIV disease according to the Centers for Disease Con-
trol and Prevention (CDC) classification system [22. 23] and a
history of:::;3 C l-type opportunistic infections. For each patient,
antibody to HIV-l had to be confirmed. p24-antigenemia had to
be detectable. and HIV-1 had to be isolated. Any antiretroviral
therapy with nucleoside analogs or cytokines was to be discon-
tinued 4 weeks before the first and until 3 weeks after the last
antibody infusion. Four weeks before the first infusion. blood
samples were obtained from 27 persons who had volunteered for
the trial; HIV -I was isolated from 17 of the volunteers. from
whom 12 were selected to participate in the trial. Participants
were selected on the basis of their reactivity with the antibody in
a specially designed gp 120 capture immunoassay (see below).
They were allocated to 3 treatment groups, each containing 4
patients.
Study Conduct and Posttreatment Surveillance
The chimeric antibody was administered by intravenous infu-
sion at 2 l-day intervals within groups (figure I). Dose was esca-
lated stepwise between groups at 7-day intervals. Group I (pa-
tients A-D). group 2 (E-H). and group 3 (I. K-M) received 1-.
10-, and 25-mg doses, respectively. Patients tolerated the first
dose. The second dose was escalated within groups (i.e., 50.
100, and 200 mg. respectively). After completion of this phase
(1), an interim analysis was done. and the trial was continued for
another six doses.
Each antibody dose was administered in 100 mL of saline
(Laboratories Hausmann, St. Gallen. Switzerland) by time-con-
trolled infusion (60 min) into a forearm vein. For each patient, a
medical history was recorded and a physical examination was
done weekly by the same physician of the study team. Venous
blood was collected between 8 and 10 A.M. before each infusion
and in weekly intervals between the infusions. Patients were
followed for 3 months after the eighth infusion (weekly for the
first 3 weeks. then once every 4 weeks). Antiretroviral medica-
tion could be resumed 3 weeks after the last infusion. All pa-
tients. including those who participated in the prestudy selec-
tion phase. received their medical care in our outpatient clinic
and were seen regularly after the study end.
Construction, Production, and Purification of the Antibody
The construction of the chimeric heavy- and light-chain genes
and the method of generating transfectomas secreting the chi-
meric antibody are described in detail [15]. The manufacture
and purification of the clinical grade antibody is also described
[19].
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Laboratory Tests
Routine tests. Hematology and clinical chemistry tests, urin-
analysis, and testing ofI32-microglobulin, neopterin, and the ma-
jor immunoglobulin classes (lgG, IgM, IgA) were done in labora-
tories at the University Hospital of Zurich.
Pharmacokinetics and anti-CGP 47 439 antibodv response. A
sandwich ELISA using a specific antiidiotypic MAb (AB 19-4) to
the chimeric antibody was used to determine serum concentra-
tions of the antibody. The chimeric antibody was used in a dou-
ble-antibody capture ELISA to detect antiidiotypic antibodies to
the chimeric antibody as a measure of immunogenicity. These
two methods, the pharmacokinetic calculations, and results of
this study were described earlier [20, 24].
gp/20 quantification and the chimeric antibody capture
ELISAs. Peripheral blood mononuclear cells (PBMC, 2-5 X
106 ) from each patient were cocultivated with 107 phytohe-
magglutinin (PHA)-stimulated PBMC from healthy blood do-
nors. The cultures were maintained in RPMl 1640 containing
15% fetal calfserum (FCS) and 40 lU/mL recombinant interleu-
kin-2 (lL-2: Boehringer, Mannheim, Germany) for ;:.3 weeks; 5
X 106 PBMC were added once a week. Culture supernatant was
assayed for HlV- I p24 antigen by ELISA (Du Pont NEN, Wil-
mington, DE). Cultures yielding ;:.20 ng/mL p24 antigen were
harvested by centrifugation, and the cell pellet was lysed with a
buffer containing nonionic detergent (I % Nonidet P-40; Sigma,
St. Louis). gp 120 in the cell lysate was measured by ELISA:
Solubilized gp 120 molecules were captured onto the solid phase
via adsorbed sheep antibody 07324 to the C-terminal 15 amino
acids of HlV-1 gpl20 (Aalto BioReagents, Dublin). Bound
gp 120 was detected with the murine MAb G3-508, which binds
to the relatively conserved C4 region of gp 120 of diverse HIV-I
isolates [25]. Bound murine antibody was detected with peroxi-
dase-conjugated goat anti-mouse immunoglobulin (Jackson
ImmunoResearch, West Grove, PA).
The amount of gp I20 in the lysates was determined from a
standard curve with purified HIV-I III B gp120. Lysates contain-
ing > 15 ng of gp 120/mL were tested in an antibody capture
ELISA to determine the specific binding of the antibody to the
gp 120 of the patient's virus isolate. The Iysates were incubated
in wells coated with antibody or with normal human IgG IK
(Sigma) as a negative control. Specific binding was detected with
biotinylated MAb G3-519, another anti-C4 region of HIV-I
gp 120 antibody that binds to the gp 120 of diverse HIV-1 vari-
ants [25]. Peroxidase-conjugated streptavidin (Jackson) was
used to detect bound antibody. A ratio of the optical density
(antibody vs. normal human IgG IK) was determined. According
to this ratio, three capture strengths were arbitrarily defined: no
capture (ratio I), weak capture (ratio between I and 2.5), and
strong capture (ratio >2.5).
Serum p24 antigen. Free serum p24 was determined unde-
natured with a commercial antigen test (p24-UD; Abbott, Ab-
bott Park, IL). To measure total (i.e., free and immunocom-
plexed) antigen, serum samples were diluted with a twofold
volume of 0.5% Triton X-IOO, heat-denatured at 100DC for 5
min (p24-HD), and tested by HlV-1 p24 core profile ELISA
(Du Pont NEN), as described [26). An ELISA amplification
system (ELAST; Du Pont NEN) was used for signal arnplifica-
tion, resulting in a detection limit of --0.5 pg/mL compared
with 12.5 pg/mL in the routinely used Abbott kit.
Lymphocyte subsets. CD3+, CD4+, and CD8+ lymphocytes
were counted in peripheral blood using routine procedures with
commercially available MAb reagents (Becton Dickinson, Ba-
sel; Coulter, Instrumenten Gesellschaft, Zurich) and flow cytom-
etry (Coulter, Instrumenten Gesellschaft).
Plasma TelD. Plasma TCID was determined as described
[27]. Decreasing volumes (500, 100, 10, and 1 JLL) of cell-free
plasma were incubated in duplicate with 2 X 106 PHA-stimu-
lated PBMC in 1.5 mL of RPMI 1640 containing 15%FCS and
40 IU/mL recombinant IL-2 in 24-well plates. After 24 h, the
cells were washed three times and maintained for 28 days, with
replenishment of medium every 3-4 days. PHA-stimulated
PBMC were added weekly, and p24 was monitored in the cul-
ture supernatants until day 28 using the Du Pont p24 core pro-
file ELISA. Cultures with>200 pg of p24/mL on 2 occasions
were considered positive. The smallest plasma volume required
to produce a positive culture was taken as the end point (2, 10,
100, or 1000 TCID/mL of plasma).
Quantitative reverse polymerase chain reaction (qrPCR).
qrPCR was done on virus particles pelleted from EDTA-plasma.
Virus was resuspended in buffer and the RNA was extracted
according to standard procedures [28, 29] using proteinase di-
gestion, phenol-chloroform extraction, and addition of carrier
tRNA for precipitation. Ten percent of the extracted viral RNA
was reverse-transcribed in a total volume of25 JLL at 3rC for 5
h with MuLV reverse transcriptase and primer SK 150 [30], us-
ing the reaction conditions recommended by the manufacturer
(Boehringer Mannheim). For amplification by PCR, the com-
plete reaction was added to 75 JLL of buffer containing primer
SK 145 [28] and Tag DNA polymerase. After amplification for
30 cycles, DNA was analyzed by Southern blot with 32P-end
labeled oligonucleotide SK I02 [28]. Radioactive bands were
counted in a beta counter.
Branched DNA (bDNA) signal amplification for HIV-/ RNA
quantitation. bONA (Chiron: Emeryville, CA) was amplified
according to the manufacturer's instructions. Virus was pelleted
at 23,000 g for I h from I mL of plasma. A viral lysate was
prepared and added to microwells. The RNA target was cap-
tured onto the microwell surface and detected via bONA ampli-
fier molecules and alkaline-phosphatase-labeled oligonucleo-
tides, and signal was generated using a chemoluminescent
substrate. Light emission is proportional to the number of HIV-
1 RNA molecules (HIV-I RNA equivalents) present in the spec-
imen [31, 32].
Statistical analysis. Analysis of covariance was done for all
surrogate markers and virus load parameters. Linear regression
analysis and Spearman's rank order correlation coefficients were
calculated to compare the different methods to measure virus
load. Survival analysis was done by Kaplan-Meier estimates
[33). p24-UD, bONA, and qrPCR results were more nearly log-
normally distributed than normally distributed; therefore, log
transformations were taken of these variables for correlation
analysis.
Results
Patient selection. HIV-1 was isolated during the preselec-
tion period from 17 of 27 patients entering the zidovudine
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Figure 2. Results of gp 120 capture assay. Capture ratio = ratio
of reactivities (optical density) between CGP 47 439-coated wells
and wells coated with normal human IgG. Patients allocated to
groups on basis of ratios.
washout phase. All isolates had positive gp 120 binding re-
sults (> 15 ng gp 120/mL of Iysate): 8 of the 17 isolates were
gp 120 capture positive. Of these, 4 showed moderate but
clear and 4 showed somewhat stronger gp 120 capture ratios
(figure 2). On the basis of these results, the patients were
allocated to the 3 treatment groups. It was hoped that pa-
tients with the strongest virus reactivity were also those who
were infected with a virus that could be neutralized by the
antibody. Therefore. group I (capture negative) was given a
low dose,S and 50 mg. of the chimeric antibody, group 2
(moderately capture positive) was given a medium dose, 10
and 100 mg, and group 3 (strongly capture positive) was
given a high dose, 25 and 200 mg.
Clinical results and survival. Nine of the 12 patients com-
pleted the study (figure I). Patient D died 3 weeks after the
second infusion. I week after a retropharyngeal lymphoma
was detected. Patient C was hospitalized I week after his fifth
infusion. with signs of cerebral toxoplasmosis, of which he
died 8 weeks later. Patient E quit the study to resume zidovu-
dine treatment after having had three antibody infusions. At
clinical follow-up, his cytomegalovirus (CMV) disease was
exacerbated and, in addition to his preexisting CMV retinitis,
a CMV stomach ulcer was diagnosed. Patient E then pre-
sented with a probably preexisting CMV-HIV encephalitis,
which progressed rapidly; he died 22 weeks after the initial
infusion. Apart from patients C, D. and K (who developed a
candida stomatitis for the first time in week 15), no other
patients progressed within the CDC HIV stage during the
study.
ABC 0 E F G H
Patients
Characteristic Group A Group B
No. of patients 12 15
Age. years (range) 39.1 38.8
(28-56) (24-53)
Time from AIDS stage IV-C2 diagnosis to
study selection (mon ths) 11.8 15.3
(3-26) (1-36)
Duration of zidovudine treatment before
study selection (months) 12.9 13.8
(4-27) (0-36)
CD4+ lyrnphocytes/rnrn ' before study
selection 80 u :
(0-230) (6-350)
Table 1. Basic characteristics of HIV-infected patients in the pre-
trial selection of participants for the clinical study.
NOTE. Group A patients, treated with CGP 47439; group B patients.
not selected. Data are mean (range).
A survival analysis comparing the 12 study patients with
15 who resumed their antiretroviral medication because they
were not selected for the study (due to their negative capture
ratio in the gp 120 capture assays) showed no statistically
significant difference between the groups (P = .95. log rank
test) (table I). The median survival time for the 12 antibody-
treated patients was 562 days (95% confidence interval [CI],
149-857 days) versus 644 days (95% CI, 255-857 days) for
the IS patients receiving antiretroviral therapy. Patient B
from group I, patient F from group 2, and patients I, K, and
L from group 3 were still alive 2.5 years after the study be-
gan. Disease progressed (i.e., new opportunistic infections or
Kaposi's sarcoma) in all of these patients after study end.
Pharmacokinetics and immunogenicity. These results
were published in detail elsewhere [24]. The mean elimina-
tion half-life (t1/2{3) of the chimeric antibody was 8-16 days.
Patients B, K, and L had marginal and transient antibodies
against the chimeric antibody. Except for patient K (see be-
low), none of these patients complained about itching or skin
rash. No correlation was observed between the presence of
the transient antibodies and the t l/2{3 of the chimeric anti-
body. Substantial serum levels of the circulating antibody
were present in all patients during the entire study (range,
0.3-30.7 ,ug/mL, depending on dose).
Safety. Patient K developed a skin rash over his entire
body 4 days after the first infusion and 9 days after beginning
treatment with arnoxicillin-clavulanic acid for external otitis.
At that time, levels of anti-CGP 47 439 antibodies were not
elevated. Aminopenicillins frequently cause skin rashes in
Hl V-infected patients, in particular as the disease progresses
[34. 35). Antibody treatment was continued with a 200-mg
dose at day 21, and six subsequent 200-mg doses were given
according to schedule with good tolerability. Patient E com-
plained about increasing tiredness after each infusion. He
elected to quit the study and resumed zidovudine therapy
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Table 2. CD4+ lymphocyte counts in Hl V-infected patients re-
ceiving infusions of the chimeric mouse-human monoclonal anti-
body (CGP 47439) directed to the V3 loop of HI V-I gp120.
C04+ lymphocytes/rnm '
Immediately
before
At zidovudine resumption of Last visit of
Patients withdrawal Day 0 zidovudine the trial"
Group 1
A 60 30 40 40
B 70 60 20 50
C 70 60 NA NA
D 0 60 NA NA
Group 2
E 10 10 40 30
F 170 100 80 70
G 0 0 (IOf 0
H 20 20 20 0
Group 3
I 170 140 30 80
K 230 200 80 30
L 140 70 30 60
M 20 10 (O)t 10
NOTE. NA, not available (patients died). Patient E died 22 weeks after
the first infusion.
* - 3 months after last infusion.
t Patients never resumed zidovudine therapy.
after the third infusion. We therefore considered that the
antibody was safe for the patients.
Clinical chemistry and urinalysis. Clinical chemistry pa-
rameters included alanine transaminase. aspartate transami-
nase. alkaline phosphatase. bilirubin, prothrombin time.
blood urea nitrogen. creatinine. glucose, and potassium.
These parameters were monitored weekly during the first 3
weeks of the trial. every 2 weeks until week 6, and every 3
weeks thereafter until the trial end. Patients showed either
changes within the normal range or no change compared
with pretrial levels (data not shown). Specifically, liver and
kidney functions yielded no evidence for immune complex
disease.
Hematology. During zidovudine treatment, all patients
had mild, moderate, or severe macrocytic anemia. The mean
corpuscular volume normalized in all 12 patients, whereas
the red blood cell counts and hemoglobin level remained
stable or improved during treatment with the antibody. After
resumption ofantiretroviraI therapy, the previously observed
macrocytic anemia reappeared. Platelets, granulocytes,
monocytes, and lymphocytes did not show significant
changes over time (data not shown). However, platelet
counts dropped 17% and 15% in patients A and L. respec-
tively, during the zidovudine washout phase.
Surrogate markers. During the trial there was consider-
able inter- and intrapatient variability of the CD4+ lympho-
cyte counts (table 2). After the trial, 5 patients (B. F, I, K,
and L) had considerably lower counts compared with those
at baseline. and 4 (A, G, H, and M) had counts that re-
mained fairly stable. Of the 3 patients who died (C-E), only
I (E) showed a slight improvement of his CD4+ lymphocyte
count. In group 3. the initial C04+ lymphocyte counts were
markedly higher than those for groups I and 2.
Levels of serum .B2-microglobulin and neopterin were ele-
vated in all patients during the entire study. An effect of
treatment was not detectable (data not shown).
Major immunoglobulin classes. Serum levels oflgG, IgM,
and IgA showed no relevant changes during the study (data
not shown).
Virologic markers. Five methods were used to measure
the patients' virus loads: concentration of undenatured viral
antigen p24 in serum (p24-UO), p24 concentration after
heat denaturation (p24-HO) for quantitative detection of
both free and immunocomplexed antigen. virion RNA in
plasma assessed by bONA amplification or qrPCR, and the
determination of infectious virus in plasma (TCID). Regres-
sion analysis of this data showed good correlations of p24-
UO and p24-HO (r = .78, P < .00 I) and of p24-HO and
bONA (r = .59, P < .00 I). In contrast, correlations of p24-
UO and bONA (r = .41, P < .00 I), bONA and qrPCR (r =
.30, P = .02), and qrPCR and p24-HO (r = -.06, P = .54)
were poor.
Plasma viremia as determined for patient K by bONA and
qrPCR analyses indicate loads of 1-6 X 105 and 3-6 X 105
virus particles/rnl., respectively (figure 3). The mean TCIO
corresponded to a mere 0.002% of these particles (range,
0.0008%-0.05%), indicating that only a minor fraction of the
particles were capable of replicating under the chosen in vi-
tro culture conditions. There was a mean of 3.2 X 103 virus
particles/ug of p24 (range, 1.4-6.1 X 103, estimated by p24-
HD and bONA). The mean was only 790 for undenatured
antigen. This is considerably below the reported 104 parti-
cles/ug of p24 [36], thus indicating that there must be forms
of antigen not associated with virus particles. Alternatively,
there may be particles that contain less than the regular 2
copies of RNA.
Table 3 summarizes treatment-associated changes of the
virus load as measured by bONA and p24-HD, the two best
correlating independent parameters. For statistical evalua-
tion, a linear regression analysis of virus load over time was
done. If available, day zero measurements were used as the
baseline; otherwise, the last measurement before day zero
was used. The analysis was otherwise restricted to the actual
time during which the patients were under antibody treat-
ment. Detailed data, expressed as percentage of the baseline
value, of selected patients in whom virus load reductions
were observed are shown in figure 4.
Antigen p24-HO was significantly reduced over time in 5
patients (B, F, G, I, and M). A parallel decrease of bONA
values occurred in patients B, F, and M: this decrease was
statistically significant in M, although only five measure-
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RNA copies
by bONA
cDNA copies
by qrPCR
Figure 3. Typical virus load pa-
rameters shown by data for patient
K. bONA (branched DNA) signal
amplification and qrPCR (quanti-
tative reverse polymerase chain re-
action) are expressed in RNA and
cDNA copies/ml, of plasma, re-
spectively: p24-UD (undenatured
p24) and p24-HD (heat-denatured
p24) are expressed in pg/ml of
serum; and TCID is expressed per
milliliter of plasma.
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ments were possible. A significant initial decrease in bONA
values up to day 86 was found in patient B; this decrease was,
however, followed by an increase resulting in an insignificant
overall decrease. Of particular interest is patient I who, de-
spite a significant reduction in antigen, showed a significant
rise in bONA. A similar situation was found in patient G,
although the increase in bONA was not significant. The
course was also remarkable in patient E, who had a highly
significant drop in bONA during the few weeks after receiv-
ing the antibody; p24 antigen during this time showed a tran-
sient peak. Patients A, 0, H, and K exhibited an initially
stable virus load, or even a decrease, followed by an increase.
No clear trend, as demonstrated by divergent results of
bONA and p24-HO values, was observed in patients C and
L; patient C had an overall increase in p24 antigen.
In conclusion, 10 patients exhibited a significant overall
change in virus load; of these, 7 indicated a reduction
(bDNA ofE and M; p24-HD ofB, F, G, I, and M) and only 3
(bDNA of I; p24-HD of C and H) indicated an increase. In
addition, patients A and B initially had transient but signifi-
cant reductions that lasted for I 1-12 weeks.
In general, the load reductions were < I log but still repre-
Table 3. Treatment-associated changes of the virus load parameters. measured by branched DNA (bDNA) signal amplification and
heat-denatured p24 (p24-HD).
Treatment p24-HD bONA
group.
patient Coefficient P r, Coefficient P r, Remarks
Group I
A 0.065 .323* .205 -0.072 .678 -.200 Stable
B -0.586 .000 -.69\ -0.\44 .285t -.370 Decrease. significant for bDNA+
C 1.100 .015 .45 [ -0.475 .641 -.429 Divergent course
0 -0.028 .983 .029 -\.597 .147 -.400 No major trend (limited data)
Group 2
E -0.489 .205 -.292 -0.902 .003 -1.000 Decrease. significant for bDNA
r -0.285 .006 -.582 -0.215 .371 -.400 Decrease. significant for p24-HD
Ci -0.216 .031 -.41\ 0.46\ .142 .345 Divergent course
H 2.391 .000 .865 0.422 .054 .6\9 Increase. significant for p24-HD
Group 3
I -0.078 .023 -.451 0.683 .035 .683 Divergent course
K 0.\61 .097 .473 0.843 .076 .550 Increase!
L 0.174 .093 .298 -0.092 .271 -.367 Stable
M -0.344 .000 -.745 -0.378 .041 -.900 Decrease. significant overall
NOTE. Bold type. significant virus load courses (P < .5). Group I. received 1- and 50-mg doses of antibody; group 2. 10- and [OO-mg doses; group 3. 25-
and 200-mg doses.
* Significant decrease of p24-HD to day 79 (P = .013). followed by increase in coincidence with erythema.
t Significant decrease of bONA to day 86 (P = .019). followed by increase.
t p24-HD undetectable within 10 weeks.
§ bONA stable to 12-15 weeks. followed by increase.
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Figure 4. Changes in p24-HD (heat-denatured p24) and bONA (branched DNA) signal amplification values for selected patients.
Results expressed as %of value on day 0 (if available) or nearest pretrial measurement. Linear regression analysis restricted to period when
patients were treated with CGP 47439. Dashed lines = beginning and end of trial.
sented a major fraction of the virus load (mean, -56%: SO,
23%~ range, -14% to -90%). In patient B, who started the
trial with a p24-HD antigen level of only 1.5 pg/mL serum,
the antigen became undetectable within 10 weeks. Reduc-
tions were not dose related: effects were evenly distributed
among the 3 treatment groups. The fraction of increases in
virus load were higher (mean, 163%; SD, 10 I%: range, 40%-
379%); they also were unrelated to dose.
Discussion
To our knowledge, this phase I/IIA trial with the chimeric
mouse-human monoclonal anti-gp 120 antibody is the first of
its kind reported. It was conducted as an uncontrolled single-
center, open-label, multidose tolerability, immunogenicity,
and pharmacokinetic study in 12 patients with advanced
HIV disease. Despite the obvious limitations of such a small
study, the extension from phase I to phase IlA was done to
evaluate any potential anti-Hl V activity of the antibody.
We recently reported that substantial serum levels of this
antibody have been maintained in our patients [24]. Mean
serum half-life of the antibody (8-16 days) was much longer
than those of murine MAbs (---15 h [37]) but shorter than
that of normal IgG (21 days [38]). Anti-antibody responses
to the chimeric antibody were found only transiently in 3
patients, and they were not associated with any clinical
symptoms or signs of adverse reactions to the antibody. A
whole-body exanthema in patient K was likely due to a toxic
reaction to amoxicillin-clavulanate, which is a well-known
effect of these drugs in AIDS patients [34, 35]. Patient E
complained of progressing tiredness after each infusion. This
finding was probably a sign of a progressing HIV-CMV en-
cephalitis and was not considered a reaction to the study
drug. In summary, the results of this phase I/IIA study in
patients with advanced HIV disease demonstrated that the
antibody was well tolerated and safe and showed low, if any,
and transient immunogenicity, which was clinically not rele-
vant. High serum levels of the antibody could be maintained.
From an ethical point of view, the withdrawal of zidovu-
dine was problematic because at that time it was the only
registered antiretroviral drug known to prolong survival in
AIDS patients [39]. Patients were informed about this
clearly. Of interest, however, no statistically significant sur-
vival differences among the 12 study patients (off zidovudine
for 7 months) and 15 patients who participated in the pretrial
selection phase (off zidovudine for I month) were observed.
The small number of patients, however, precludes an analy-
sis of efficacy. At best. we could speculate that withdrawal of
zidovudine did not influence survival. The hematologic data
from the 12 patients strongly suggest that they did not se-
cretly take zidovudine during the trial. During zidovudine
treatment, all 12 patients had a moderate macrocytic ane-
mia, a frequent side effect of zidovudine [40, 41]. Discontin-
uation of zidovudine was followed by normalization of the
mean corpuscular volume, a rapid increase of red blood cell
counts, and, somewhat less pronounced, an increase in hemo-
globin level in all patients. The opposite effects were ob-
served when zidovudine treatment was resumed.
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Three patients were still alive in group 3 (strongly capture
positive) 2-1/2 years after the first infusion, compared with
only I patient each in groups 1 and 2. Although interesting,
this difference cannot be interpreted to indicate a dose-de-
pendent therapeutic effect on survival for the following rea-
sons: The number of patients in each group is too small to do
a multivariate analysis to detect the relevant factors for the
difference in survival between groups; group 3 patients had
the highest pretrial mean CD4+ lymphocyte counts; and pa-
tients were not randomly assigned to the 3 treatment groups
but selected according to their gp 120 capture ratio.
Some antibodies to the gp 120 envelope protein of HIV-l
may enhance HIV infection in vitro [40-44]. In addition, a
correlation ofantibody-dependent enhancement ofinfection
with disease progression in HIV-infected persons has been
reported [45]. A recent study showed that neutralizing and
enhancing antibodies can be induced by different epitopes
on gp 120 [46]. The antibody has been shown not to enhance
HIV-I infection in vitro (data not shown) and in hu-PBL-
SCIO mice studies [18]. Another recently chimerized mouse-
human MAb specific to the PND ofgp 120 showed anti-HI V
activities similar to those reported for the antibody [47]. It
exhibited no enhancement in vitro and the authors suggested
that neutralizing antibodies to PND neutralize but do not
enhance HIV infection. In agreement with these in vitro ob-
servations, the lack of any clinical evidence of a faster pro-
gression to death in our patients compared with the 15 pa-
tients without the chimeric antibody and the absence of a
dose-related p24 increase after the infusions suggest that
there was no antibody-dependent enhancement of HI V-I in-
fection.
In this study, considerable effort was made to measure
virus load in the treated patients. It was known that in vitro
the antibody was able to neutralize effectively the infectivity
of HIV -I IIIB and weakly that of HIV-I MN [13, 14]. HIV -1MN-
related strains were reported to be prevalent in HIV -I-in-
fected persons [48-50]. We therefore developed a gp 120
capture assay to select patients infected with the antibody-
reactive HIV-I strains. Eight of 17 patients who showed suf-
ficient virus growth also showed gp 120 capture. We adminis-
tered the highest dose to patients with the highest gp 120
reactivity, thereby increasing the 1ikelihood ofobserving pos-
sible antiviral activity of the antibody yet fully aware of the
negative consequences on the statistical analysis of the out-
come.
All patients showed considerable viremia confirmed by
different methods: p24-UO, p24-HD, qrPCR, bONA signal
amplification. and TCID. qrPCR and TClO showed wide
intrapatient variations and were not sensitive enough to de-
tect slight changes in virus load. However, bONA and p24-
HO analyses provided results that allowed measurement of
changes in virus load. The different slopes of these parame-
ters suggest that some p24 antigen is not associated with
virus particles (data not shown).
bONA and p24-HO analyses indicated a significant anti-
viral effect in patients B, F, G, I, and M. In addition, signifi-
cant initial reductions in either bONA or p24-HD values
were observed in patients A and E. In patients Hand K, one
or both parameters remained stable compared with the pre-
dose (day zero) level for several months before significant
increases in virus load occurred. Reductions were generally
< 1 log, but were frequently most of the circulating virus and,
thus, may be of biologic significance.
In contrast to our expectations, the antiviral effects were
evenly distributed between all 3 treatment groups. There is
no correlation between the demonstrated an ti-H IV-I effect
and the gp 120 reactivity with the antibody or doses used.
This may be attributed to the fact that the cultured virus used
for the gp 120 capture assay was not representative of the
circulating virus predominant in vivo: The procedure used to
isolate virus might select a fraction ofthe clinical viruses with
rapid and high replication capacities.
The antibody may have several mechanisms of antiviral
action. It may neutralize in vivo the infectivity of free virus.
Alternatively, the transient initial increase in particle-asso-
ciated RNA (figure 4) may indicate the lysis of HIV-l-in-
fected cells by antibody-dependent cellular cytotoxicity [15]
or complement-mediated lysis [51, 52]. The fact that treat-
ment with the neutralizing antibody resulted in reductions in
the virus load in some patients is encouraging and indicates
that additional clinical studies with this chimeric antibody
are warranted. In addition, since it has been shown that com-
binations of MAbs may have synergistic effects in vitro [53,
54], and to prevent the possible emergence of escape mu-
tants, cocktails of antibodies recognizing different neutraliz-
ing epitopes also should be considered for further studies.
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